NCT03723304 is a clinical trial of Bridging followed by transplant in Liver Cancer, sponsored by European Hepatocellular Cancer Liver Transplant Group.

Who is sponsoring NCT03723304?

NCT03723304 is sponsored by European Hepatocellular Cancer Liver Transplant Group.

What drugs are being tested in NCT03723304?

Interventions in NCT03723304: Bridging followed by transplant, Direct liver transplant.

What condition does NCT03723304 study?

NCT03723304 studies Liver Cancer, Transplant; Failure, Liver.

Is NCT03723304 still recruiting?

NCT03723304 is currently completed. Last updated 29 October 2018.

Last reviewed 2018-10-29 · How we verify

NCT03723304

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Intention-to-treat Effect of Bridge Therapies in the Setting of Milan-in Patients

Completed Last updated 29 October 2018

What this trial tests

trial testing Bridging followed by transplant in Liver Cancer in 1,083 participants. Completed in 15 October 2018.

Timeline

1 March 2018

Primary endpoint
15 October 2018

15 October 2018

Quick facts

Lead sponsor	European Hepatocellular Cancer Liver Transplant Group
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,083
Start date	1 March 2018
Primary completion	15 October 2018
Estimated completion	15 October 2018
Sites	1 location across Belgium

Drugs / interventions tested

Bridging followed by transplant
Direct liver transplant

Conditions studied

Liver Cancer — all drugs for Liver Cancer →
Transplant; Failure, Liver — all drugs for Transplant; Failure, Liver →

Sponsor

European Hepatocellular Cancer Liver Transplant Group

Who can join

Adults 18 to 70, any sex, with Liver Cancer or Transplant; Failure, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In patients with hepatocellular cancer (HCC) meeting the Milan Criteria (MC), the usefulness of loco-regional therapies (LRT) in the context of liver transplantation (LT) is still debated. The inconsistent literature data are the result of initial selection biases among treated and untreated patients. In order to overcome these shortcomings, an inverse probability of treatment weighting (IPTW) analysis was done in a large patient cohort. After using a competing-risk analysis, the primary end-point of the study aims at identifying the risk factors of HCC-specific LT failure, defined as pre-LT tumour-related drop-out or post-LT recurrence.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation.
Lai Q, Vitale A, Iesari S, Finkenstedt A, et al · · 2019 · cited 33× · PMID 31087772 · DOI 10.1002/lt.25492

Verify or expand the search:

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting

Other European Hepatocellular Cancer Liver Transplant Group trials

Trials by the same sponsor.

NCT05200195 — Deep Learning Model for the Prediction of Post-LT HCC Recurrence · completed
NCT03723317 — Associated Balance of Risk Score - Comprehensive Complication Index for the Prediction of Post-transplant Survival · completed
NCT03595345 — A Worldwide Score for Hepatocellular Cancer and Liver Transplantation · completed
NCT06799468 — Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03723304 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Hepatocellular Cancer Liver Transplant Group
Last refreshed: 29 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03723304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing